Treatment with a RIPK2 inhibitor at the onset of reperfusion after MCAO attenuated the RIPK2 phosphorylation induced by stroke and significantly reduced infarct volume and blood–brain barrier (BBB) disruption [14]. This evidence concerns the gene RIPK2 and Stroke.